Paper No. _____ Filed: September 21, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC, INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., MYLAN INC., LUPIN LTD. and LUPIN PHARMACEUTICALS INC., Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD., Patent Owner

Case IPR2015-00903 (Patent 8,129,431 B2)¹

PATENT OWNER'S MOTION TO EXPUNGE UNDER 37 C.F.R. § 42.56

¹ Case IPR2015-01871 has been joined with this proceeding.



I. Statement of Relief Requested

Pursuant to 37 C.F.R. § 42.56, Patent Owner requests that the Board expunge from the record the confidential versions of Paper Nos. 33, 34, and Exs. 1079, 1081, 1082, 1150, 2096, 2102, 2103, 2110, 2116, 2130 and 2273 for the reasons stated herein.

II. Background

On July 29, 2016, Patent Owner filed a Renewed Motion to Seal concerning a number of Patent Owner's exhibits, listed below (*see* Paper No. 86), and on August 1, 2016, Patent Owner filed a Second Renewed Motion to Seal concerning additional exhibits, also listed below, (*see* Paper No. 89). On August 29, 2016, the Board granted Patent Owner's two motions to seal (*see* Paper Nos. 91, 93), sealing all or portions of the following papers and exhibits:

• Patent Owner's Response (citing to confidential exhibits), Paper Nos. 33 and 34 (filed December 28, 2015).



- Excerpts to Patent Owner's New Drug Application: Ex. 2096 (filed July 29, 2016); Ex. 2102 (filed July 29, 2016); Ex. 2103 (filed July 29, 2016); Ex. 2110 (filed July 29, 2016)².
- Expert Declarations: Williams (Ex. 2082) (filed Dec. 28, 2015); Trattler (Ex. 2116) (filed July 29, 2016); and Jarosz (Ex. 2130) (filed July 29, 2016).³
- Transcripts of Expert Cross Examinations: Mr. Hofmann (Ex. 2273) (filed July 29, 2016); Dr. Paulson (Ex. 1082) (filed March 18, 2016); Dr. Trattler (Ex. 1081) (filed March 18, 2016); and Dr. Williams (Ex. 1079) (filed March 18, 2016).

As outlined in the Joint Stipulation filed herewith, in its Final Written Decision of July 28, 2016, the Board referred to paragraphs containing sealed, confidential information, in the following papers and exhibits:

³ Revised, confidential versions of Exs. 2116, and 2130 were filed on July 29, 2016 to conform with the marking requirements of the Default Protective Order and to remove redactions to information (specifically expert testimony) which Patent Owner no longer sought to seal.



² Revised, confidential versions of Exs. 2096, 2102, 2103, and 2110 were filed on July 29, 2016 to conform with the marking requirements of the Default Protective Order.

- Patent Owner's Response (Paper No. 34),
- Hofmann Declaration (Ex. 1150),
- Williams Declaration (Ex. 2082),
- Trattler Declaration (Ex. 2116), and
- Jarosz Declaration (Ex. 2130).

As also noted in the Joint Stipulation, the parties will file revised, public versions of Patent Owner's Response and Exs. 1150, 2082, 2116, and 2130, leaving unredacted the portions of those papers and exhibits cited by the Board in the Final Written Decision.

III. Reasons for the Relief Requested

In the Board's Order of September 19, 2016, the Board authorized an extension of time to file this Motion to Expunge. (*See* Paper No. 95.) In that same Order, the Board noted that it would not entertain a motion to expunge with respect to confidential information cited in the Board's Final Written Decision. *Id.* at 3. Accordingly, Patent Owner requests the following papers and exhibits containing confidential information sealed by the Board, but not referred to in the Board's Final Written Decision, be expunged from the record:

Patent Owner's Response (citing the confidential information), Paper Nos.
 33 and 34 (filed December 28, 2015).



- Excerpts to Patent Owner's New Drug Application: Ex. 2096 (filed July 29, 2016); Ex. 2102 (filed July 29, 2016); Ex. 2103 (filed July 29, 2016); Ex. 2110 (filed July 29, 2016).
- Confidential versions of Expert Declarations: Hofmann (Ex. 1150); Trattler
 (Ex. 2116); and Jarosz (Ex. 2130).
- Confidential versions of transcripts of Expert Cross Examinations: Mr.
 Hofmann (Ex. 2273) (filed July 29, 2016); Dr. Paulson (Ex. 1082) (filed March 18, 2016); Dr. Trattler (Ex. 1081) (filed March 18, 2016); and Dr.
 Williams (Ex. 1079) (filed March 18, 2016).

Because the public has access to all the materials relevant to the merits of this proceeding, either through publicly filed papers and exhibits or through redacted, public versions of Patent Owner's Response (Paper No. 34), Hofmann Declaration (Ex. 1150), Williams Declaration (Ex. 2082), Trattler Declaration (Ex. 2116), and the Jarosz Declaration (Ex. 2130) filed herewith, and given the sensitive and confidential nature of the sealed information, good cause exists for the Board to expunge the papers and exhibits listed above pursuant to 37 C.F.R. § 42.56.

Moreover, Patent Owner submits that the exhibits listed above continue to contain confidential information and that expunging the them from the record will not hamper the public interest of maintaining a complete and understandable file



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

